Dyne Therapeutics opened lower at $17.70, compared with its previous close of $17.99. In the last trading session, the stock traded between $17.03 and $17.78. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Dyne Therapeutics is now worth
$ 119.84
Giving a profit of
$ 19.84 (19.84%)
Note: Past profits do not guarantee future returns.
Rating from 11 Analysts
Today's Change
$-0.96 (-5.34%)
Day High
$17.78
Day Low
$17.03
Day Open
$17.70
Prev Close
$17.99
Volume
18,54,649
1W Return
-8.21%
1M Return
6.64%
3M Return
-36.25%
6M Return
-7.75%
1Y Return
-13.43%
Market Cap ($ Mn)
3,191
PE Ratio
-
PB Ratio
5.92
PEG Ratio
-
ROE
-63.13%
ROCE
-59.22%
EPS (TTM)
$-1.03
1 Week
-8.21%
1 Month
6.64%
3 Months
-36.25%
6 Months
-7.75%
9 Months
2.09%
Dyne Therapeutics Q3 Results: Loss widens 39% YoY to $1.06 per share
Dyne Therapeutics posted a Q3 loss of $1.06 per share, up 39.47% YoY from $0.76. The result missed the analyst consensus estimate of $0.92 by 15.22%. Losses widened significantly compared to the same period in the previous year.
7 days agoDyne Therapeutics reports 1-year ACHIEVE data for DM1 candidate
Dyne reported 12-month data from ACHIEVE trial showing functional improvement vs baseline, placebo, and natural history. Pooled MAD group showed 3.2 second decrease in vHOT at 6 months vs 0.4 second increase in placebo. Mean baseline vHOT in Registrational Expansion Cohort (REC) confirmed at 8.3 seconds. Topline data from REC expected in Q1 2027 to support U.S. Accelerated Approval submission.
1mo agoDyne Therapeutics grants equity awards to 14 new hires
Dyne Therapeutics granted equity awards to 14 new employees. Awards include 278,100 stock options and 88,400 RSUs. Grants comply with Nasdaq Listing Rule 5635(c)(4). Options vest over four years with 25% cliff after one year. RSUs vest in four equal annual installments.
1mo agoDyne Therapeutics shares fall 14.66% after Novartis trial failure
Dyne Therapeutics shares fell 14.66% to $20.72 on Tuesday. Novartis failed to meet primary endpoint in Phase 3 HARBOR DM1 study. Dyne to present one-year Phase 1/2 ACHIEVE trial data at upcoming conferences. Registrational expansion cohort enrollment completed with 71 participants. Phase 3 HARMONIA trial initiated with FDA-aligned protocol.
2mo agoDyne Therapeutics to present preclinical data for four DMD candidates at NMSG
Dyne Therapeutics to present preclinical data for four DMD candidates at NMSG. Candidates target exon skipping for exons 53, 45, 44 and 55. All programs advance into IND-enabling studies using FORCE platform. Lead candidate z-rostudirsen remains under FDA review for exon 51 DMD.
2mo agoDyne Therapeutics to participate in three September healthcare conferences
Dyne Therapeutics (NASDAQ: DYN) to hold fireside chats at three major healthcare conferences in September 2026. Events include Cantor Global Healthcare Conference on September 11 and Morgan Stanley conference on September 14. Baird Global Healthcare Conference appearance scheduled for September 15, all sessions in New York. Live webcasts and 90-day replays available on company investor website.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Dyne Therapeutics is now worth
$ 119.84
Giving a profit of
$ 19.84 (19.84%)
Note: Past profits do not guarantee future returns.
